On Friday, Shares of eBay Inc (NASDAQ:EBAY), added 1.21% and closed at $31.89 in the last trading session. The last trading range of the stock ranges between $31.60 and $32.24. eBay Inc. operates e-commerce platforms that connect various buyers and sellers worldwide. Its platforms facilitate sellers to organize and offer inventory for sale; and buyers to find and buy it virtually anytime and anywhere. The companys Marketplace platforms include its online marketplace at ebay.com and the eBay mobile apps; and StubHub platforms comprise its online ticket platform at stubhub.com and the StubHub mobile apps, which facilitate fans to purchase tickets to the games, concerts, and theater shows. Its Classifieds platforms include a collection of brands, such as Mobile.de, Kijiji, Gumtree, Marktplaats, eBay Classifieds, and others that offer online classifieds and assist people find whatever they are looking for in their local communities.
Kinross Gold Corporation (USA) (NYSE:KGC), dropped -3.47% and closed at $3.62 in the last trading session. The last trading range of the stock ranges between $3.59 and $3.76. The company’s Market capitalization is $4.34 Billion with the total Outstanding Shares of 1.24 billion. Kinross Gold Corporation (TSX:K.TO) (KGC) is happy to declare that it has agreed to a new three-year collective labour agreement (CLA) with unionized employees at its Tasiast mine in Mauritania.
As formerly declared in its Q2 2016 results news release, the Company and the Government of Mauritania have also agreed to a “Mauritanization” plan to increase the number of local workers at Tasiast, a requirement under Mauritanian law. Tasiast resumed normal mining and processing activities in mid-August after resolving the expatriate work permit issue, which was part of the Mauritanization plan agreement.
Bristol-Myers Squibb Co (NYSE:BMY), lost -0.94% and closed at $49.77 in the last trading session. The last trading range of the stock ranges between $49.76 and $50.65. The company’s Market capitalization is $82.38 Billion with the total Outstanding Shares of 1.66 billion. During the 52-week trading session the minimum price at which share price traded, registered at $49.12 and reached to max level of $77.12. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989.